NCT00383994View on ClinicalTrials.gov

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions
LymphomaLeukemiaTransplantation, Stem CellLymphoid MalignanciesDisorder Related to Transplantation
Interventions
DRUG

GM-CSF

250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.

DRUG

Rituximab

375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.

BIOLOGICAL

NK Cell Infusion

NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00383994 - Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter